Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IMUC Stock Summary
In the News
ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market
LOS ANGELES, June 28, 2021 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021.
IMUC Financial details
Company Rating
Buy
Market Cap
31.02M
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
13 Mar 2024
P/E
-0.09
Forward P/E
-
PEG
-
P/S
-
P/B
0.36
P/C
-
P/FCF
-2.72
Quick Ratio
2.81
Current Ratio
2.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-17.86%
SMA50
-42.5%
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-264%
ROE
-344%
ROC
-4.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
113.27M
Shs Float
112.95M
-
-
-
-
Target Price
-
52W Range
0.151-0.4
52W High
-
52W Low
-
RSI
40.27
Rel Volume
18.02
Avg Volume
2.12K
Volume
38.12K
Perf Week
-17.19%
Perf Month
-36.9%
Perf Quarter
-26.21%
Perf Half Y
-34.64%
-
-
-
-
Beta
1.377
-
-
Volatility
0.03%, 0.03%
Prev Close
-20.43%
Price
0.183
Change
-8.5%
IMUC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2016-12-31 | 2017-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -83.6 | -4.42 | -0.03 | -0.05 | 0 | |
Operating cash flow per share | -70.97 | -3.98 | -0.03 | -0.02 | 0 | |
Free cash flow per share | -70.99 | -3.98 | -0.03 | -0.02 | 0 | |
Cash per share | 40.86 | 1.58 | 0.01 | 0.01 | 0 | |
Book value per share | 21.91 | 1.11 | 0 | -0.01 | 0 | |
Tangible book value per share | 21.91 | 1.11 | 0 | -0.01 | 0 | |
Share holders equity per share | 21.91 | 1.11 | 0 | -0.01 | 0 | |
Interest debt per share | 4.69 | 0.21 | 0 | 0.02 | 0 | |
Market cap | 5.74M | 13.24M | 21.19M | 47.57M | 92.85K | |
Enterprise value | -5.7M | 6.61M | 20.92M | 48.9M | 92.85K | |
P/E ratio | -0.25 | -0.72 | -14.58 | -9.24 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.29 | -0.79 | -17.13 | -20.63 | 0 | |
PFCF ratio | -0.29 | -0.79 | -17.13 | -20.63 | 0 | |
P/B Ratio | 0.94 | 2.85 | 163.5 | -29.44 | 0 | |
PTB ratio | 0.94 | 2.85 | 163.5 | -29.44 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.23 | -0.31 | -14.4 | -18.71 | 0 | |
EV to operating cash flow | 0.29 | -0.4 | -16.91 | -21.2 | 0 | |
EV to free cash flow | 0.29 | -0.4 | -16.91 | -21.2 | 0 | |
Earnings yield | -4.08 | -1.4 | -0.07 | -0.11 | 0 | |
Free cash flow yield | -3.46 | -1.26 | -0.06 | -0.05 | 0 | |
Debt to equity | 0 | 0 | 0 | -1.74 | 0 | |
Debt to assets | 0 | 0 | 0 | 1.69 | 0 | |
Net debt to EBITDA | 0.47 | 0.31 | 0.18 | -0.51 | 0 | |
Current ratio | 4.14 | 2.97 | 1.92 | 3.58 | 0 | |
Interest coverage | -18.38 | -23.96 | 0 | -308.85 | 0 | |
Income quality | 0.9 | 1.16 | 0.85 | 0.45 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.05 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 202.99 | 10.5 | 0.05 | 0.12 | 0 | |
ROIC | -4.17 | -5.89 | -11.2 | -2.18 | 0 | |
Return on tangible assets | -1.39 | -2.64 | -5.45 | -3.09 | 0 | |
Graham Net | 4.54 | 1.02 | 0 | -0.02 | 0 | |
Working capital | 10.18M | 4.65M | 125.85K | 1.2M | 0 | |
Tangible asset value | 6.13M | 4.65M | 129.58K | -1.62M | 0 | |
Net current asset value | 2.66M | 4.65M | 125.85K | -1.62M | 0 | |
Invested capital | 0 | 0 | 0 | -1.74 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.25M | 1.56M | 0 | 0 | 0 | |
Average inventory | 593.09K | 593.09K | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -3.82 | -3.98 | -11.21 | 3.19 | 0 | |
Capex per share | -0.01 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.01 | 0 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0.01 | 0 | 0 | 0 | 0 | |
Book value per share | -0.05 | 0 | 0 | 0 | 0 | |
Tangible book value per share | -0.05 | 0 | 0 | 0 | 0 | |
Share holders equity per share | -0.05 | 0 | 0 | 0 | 0 | |
Interest debt per share | 0.04 | 0 | 0 | 0 | 0 | |
Market cap | 64.09K | 0 | 0 | 0 | 0 | |
Enterprise value | 63.54K | 0 | 0 | 0 | 0 | |
P/E ratio | -21 | 0 | 0 | 0 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | -17.19 | 0 | 0 | 0 | 0 | |
PTB ratio | -17.19 | 0 | 0 | 0 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -783.32 | 0 | 0 | 0 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | -0.01 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | -0.82 | 0 | 0 | 0 | 0 | |
Debt to assets | 4.27 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 6.79 | 0 | 0 | 0 | 0 | |
Current ratio | 0.97 | 0 | 0 | 0 | 0 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.1 | 0 | 0 | 0 | 0 | |
ROIC | 0.9 | 0 | 0 | 0 | 0 | |
Return on tangible assets | -1.07 | 0 | 0 | 0 | 0 | |
Graham Net | -0.05 | 0 | 0 | 0 | 0 | |
Working capital | -20.25 | 0 | 0 | 0 | 0 | |
Tangible asset value | -3.73K | 0 | 0 | 0 | 0 | |
Net current asset value | -3.73K | 0 | 0 | 0 | 0 | |
Invested capital | -0.82 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.2 | 0 | 0 | 0 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
IMUC Frequently Asked Questions
What is ImmunoCellular Therapeutics, Ltd. stock symbol ?
ImmunoCellular Therapeutics, Ltd. is a US stock , located in Montvale of Nj and trading under the symbol IMUC
What is ImmunoCellular Therapeutics, Ltd. stock quote today ?
ImmunoCellular Therapeutics, Ltd. stock price is $0.183 today.
Is ImmunoCellular Therapeutics, Ltd. stock public?
Yes, ImmunoCellular Therapeutics, Ltd. is a publicly traded company.